CING Stock Overview A biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Cingulate Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cingulate Historical stock prices Current Share Price US$4.78 52 Week High US$114.24 52 Week Low US$1.80 Beta -0.79 1 Month Change 13.81% 3 Month Change -4.97% 1 Year Change -94.79% 3 Year Change -99.28% 5 Year Change n/a Change since IPO -99.55%
Recent News & Updates
The Nasdaq Hearings Panel Grants Cingulate's Request for an Exception to Demonstrate Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing Through August 23, 2024 Aug 08
Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market Jun 19
Cingulate Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605 Feb 27
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors Feb 13 Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Feb 07
See more updates
The Nasdaq Hearings Panel Grants Cingulate's Request for an Exception to Demonstrate Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing Through August 23, 2024 Aug 08
Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market Jun 19
Cingulate Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605 Feb 27
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors Feb 13 Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Feb 07
Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million. Feb 03
Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer Jan 30
Cingulate Inc. has filed a Follow-on Equity Offering in the amount of $26 million. Jan 13
Cingulate Receives Non-Compliance Notice from Nasdaq Dec 29
Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer Dec 16
Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors Dec 13
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103 (Buspirone) Dec 02 Cingulate Inc. has filed a Follow-on Equity Offering. Nov 17
The Listing Qualifications Staff of The Nasdaq Stock Market LLC Determines to Delist Cingulate's Securities from Nasdaq Unless it Timely Requests Hearing Before the Nasdaq Hearings Panel Nov 15
Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it’s Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations Oct 20 Cingulate Weighs Reverse Stock Split to Avoid Delisting Sep 29
Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $4 million. Sep 15
New major risk - Shareholder dilution Sep 14
New major risk - Negative shareholders equity Aug 17
Cingulate Inc. Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement Aug 02
Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd Jul 12
Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August Jun 30
New major risk - Market cap size Jun 17
Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd Jun 09
Cingulate Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement May 22
Cingulate Inc., Annual General Meeting, Jun 15, 2023 May 06
Forecast to breakeven in 2025 May 06
No longer forecast to breakeven Mar 12
Cingulate Inc. Announces Resignation of Jeff Conroy from the Board of Directors Jan 10
Cingulate Inc. Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD Jan 05
Independent Director recently bought US$75k worth of stock Nov 27
Cingulate Inc. Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD Nov 02
Cingulate Inc. Provides Clinical Update Oct 25
Cingulate Inc. Announces the Resignation of Jeff Hargroves from the Board of Directors Sep 30
Cingulate Presents Data for its Triple-Release Buspirone Product Candidate: CTx-2103 Sep 20
Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation Aug 26
Cingulate Inc. Appoints Scott Applebaum as Class III Director Aug 12
Cingulate Q2 GAAP EPS of -$0.36 Aug 11
Cingulate Inc. Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders Jun 24 Cingulate Inc. Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders May 25
Cingulate Inc. Announces First Subject Dosing in its Human Formulation Study of CTX-2103 (Buspirone) for the Treatment of Anxiety May 13
Cingulate Inc., Annual General Meeting, Jun 08, 2022 Apr 23
Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans? Apr 04
Independent Director recently bought US$89k worth of stock Mar 23
Cingulate Inc Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD) Feb 09 Shareholder Returns CING US Pharmaceuticals US Market 7D 16.6% 1.3% 0.6% 1Y -94.8% 8.0% 23.8%
See full shareholder returns
Return vs Market: CING underperformed the US Market which returned 24.6% over the past year.
Price Volatility Is CING's price volatile compared to industry and market? CING volatility CING Average Weekly Movement 13.0% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CING's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CING's weekly volatility has decreased from 50% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety.
Show more Cingulate Inc. Fundamentals Summary How do Cingulate's earnings and revenue compare to its market cap? CING fundamental statistics Market cap US$15.48m Earnings (TTM ) -US$16.35m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CING income statement (TTM ) Revenue US$0 Cost of Revenue US$10.10m Gross Profit -US$10.10m Other Expenses US$6.25m Earnings -US$16.35m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 11:23 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cingulate Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Edward Woo Ascendiant Capital Markets LLC Jason McCarthy Maxim Group Nazibur Rahman Maxim Group
Show 1 more analysts 
